{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T21:48:17Z","timestamp":1774388897110,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Backround<\/jats:bold>\n                    : Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism caused by heterozygous, inherited, or de novo activating mutations in the calcium-sensing receptor gene (CASR).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Case presentation<\/jats:bold>\n                    : A 29-year-old man was referred to the outpatient department for poorly controlled hypoparathyroidism with hypocalcemia, hypomagnesemia, mild hypokalemia, excessive hypercalciuria, and a worsening eGFR under conventional therapy. He was diagnosed with hypoparathyroidism on the second day of birth. He remained inadequately controlled even after the initiation of replacement therapy with rhPTH (1\u201384). He was also diagnosed with chronic myelogenous leukemia (CML) at the age of 28 years and was treated with tyrosine kinase inhibitor (TKI), which further worsened the control of hypoparathyroidism. Genetic analysis was performed at the age of 31 years and revealed a change c.2486\u00a0A\u2009&gt;\u2009G in exon 7 of the\n                    <jats:italic>CaSR<\/jats:italic>\n                    gene.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : This case highlights the importance of characterizing the cause of non-surgical hypoparathyroidism, including ADH1, in the differential diagnosis. ADH1 may coexist with Bartter syndrome type V, making the patient\u2019s management more challenging. To our knowledge, this is the second case in the literature with the coexistence of two rare diseases, ADH1 and CML.\n                  <\/jats:p>\n                  <jats:p>In CML patients treated with TKIs, serum calcium levels should be monitored and, in the case of severe hypocalcemia accompanied by low or inappropriately normal PTH, the possible existence of ADH1 may need to be investigated.<\/jats:p>","DOI":"10.1007\/s42000-025-00706-7","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T23:35:24Z","timestamp":1754350524000},"page":"283-288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An interesting case of coexistence of autosomal dominant hypocalcemia 1 with Bartter syndrome and chronic myelogenous leukemia"],"prefix":"10.1007","volume":"25","author":[{"given":"Maria Eleni","family":"Chondrogianni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Kaperda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kyrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpal S.","family":"Randeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elpis","family":"Vlachopapadopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-2297","authenticated-orcid":false,"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","volume":"105","author":"JP Bilezikian","year":"2020","unstructured":"Bilezikian JP (2020) Hypoparathyroidism. J Clin Endocrinol Metab 105:1722\u20131736. https:\/\/doi.org\/10.1210\/clinem\/dgaa113","journal-title":"J Clin Endocrinol Metab"},{"key":"706_CR2","doi-asserted-by":"crossref","unstructured":"Hakami Y, Khan A (2019) Hypoparathyroidism. pp 109\u2013126","DOI":"10.1159\/000491042"},{"key":"706_CR3","doi-asserted-by":"publisher","unstructured":"Roszko KL, Bi RD, Mannstadt M (2016) Autosomal dominant hypocalcemia (Hypoparathyroidism) types 1 and 2. https:\/\/doi.org\/10.3389\/fphys.2016.00458. Front Physiol 7:","DOI":"10.3389\/fphys.2016.00458"},{"key":"706_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02496-y","author":"T De Coster","year":"2024","unstructured":"De Coster T, David K, Breckpot J, Decallonne B (2024) Management of autosomal dominant hypocalcemia type 1: literature review and clinical practice recommendations. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-024-02496-y","journal-title":"J Endocrinol Invest"},{"key":"706_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3390\/children10061011","volume":"10","author":"RI Teleanu","year":"2023","unstructured":"Teleanu RI, Sarman MA, Epure DA et al (2023) Autosomal dominant hypocalcemia type 1 and neonatal focal seizures. Children 10:1011. https:\/\/doi.org\/10.3390\/children10061011","journal-title":"Children"},{"key":"706_CR6","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/jbmr.4659","volume":"37","author":"KL Roszko","year":"2020","unstructured":"Roszko KL, Stapleton Smith LM, Sridhar AV et al (2020) Autosomal dominant hypocalcemia type 1: A systematic review. J Bone Min Res 37:1926\u20131935. https:\/\/doi.org\/10.1002\/jbmr.4659","journal-title":"J Bone Min Res"},{"key":"706_CR7","doi-asserted-by":"publisher","unstructured":"Khan AA, Bilezikian JP, Brandi ML et al (2020) Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop. J Bone Miner Res 37:2568\u20132585. https:\/\/doi.org\/10.1002\/jbmr.4691","DOI":"10.1002\/jbmr.4691"},{"key":"706_CR8","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/hmg\/dds105","volume":"21","author":"FM Hannan","year":"2012","unstructured":"Hannan FM, Nesbit MA, Zhang C et al (2012) Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet 21:2768\u20132778. https:\/\/doi.org\/10.1093\/hmg\/dds105","journal-title":"Hum Mol Genet"},{"key":"706_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/IJNRD.S155397","volume":"11","author":"T Cunha","year":"2018","unstructured":"Cunha T, da Heilberg S IP (2018) Bartter syndrome: causes, diagnosis, and treatment. Int J Nephrol Renovasc Dis Volume 11:291\u2013301. https:\/\/doi.org\/10.2147\/IJNRD.S155397","journal-title":"Int J Nephrol Renovasc Dis Volume"},{"key":"706_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12519-020-00370-4","volume":"17","author":"FCC Mrad","year":"2021","unstructured":"Mrad FCC, Soares SBM, de Menezes Silva LAW et al (2021) Bartter\u2019s syndrome: clinical findings, genetic causes and therapeutic approach. World J Pediatr 17:31\u201339. https:\/\/doi.org\/10.1007\/s12519-020-00370-4","journal-title":"World J Pediatr"},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3345\/kjp.2015.58.4.148","volume":"58","author":"KH Choi","year":"2015","unstructured":"Choi KH, Shin CH, Yang SW, Cheong H, Il (2015) Autosomal dominant hypocalcemia with Bartter syndrome due to a novel activating mutation of calcium sensing receptor, Y829C. Korean J Pediatr 58:148. https:\/\/doi.org\/10.3345\/kjp.2015.58.4.148","journal-title":"Korean J Pediatr"},{"key":"706_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","volume":"15","author":"FM Hannan","year":"2019","unstructured":"Hannan FM, Kallay E, Chang W et al (2019) The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol 15:33\u201351. https:\/\/doi.org\/10.1038\/s41574-018-0115-0","journal-title":"Nat Rev Endocrinol"},{"key":"706_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11899-018-0474-6","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Medeiros LJ, Hu S (2018) Chronic myeloid leukemia: beyond BCR-ABL1. Curr Hematol Malig Rep 13:435\u2013445. https:\/\/doi.org\/10.1007\/s11899-018-0474-6","journal-title":"Curr Hematol Malig Rep"},{"key":"706_CR14","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1038\/s41467-023-41770-0","volume":"14","author":"RS Pereira","year":"2023","unstructured":"Pereira RS, Kumar R, Cais A et al (2023) Distinct and targetable role of calcium-sensing receptor in leukaemia. Nat Commun 14:6242. https:\/\/doi.org\/10.1038\/s41467-023-41770-0","journal-title":"Nat Commun"},{"key":"706_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/jbmr.3747","volume":"34","author":"MS Roberts","year":"2019","unstructured":"Roberts MS, Gafni RI, Brillante B et al (2019) Treatment of autosomal dominant hypocalcemia type 1 with the calcilytic NPSP795 (SHP635). J Bone Min Res 34:1609\u20131618. https:\/\/doi.org\/10.1002\/jbmr.3747","journal-title":"J Bone Min Res"},{"key":"706_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1056\/NEJMc2302708","volume":"389","author":"RI Gafni","year":"2023","unstructured":"Gafni RI, Hartley IR, Roszko KL et al (2023) Efficacy and safety of Encaleret in autosomal dominant hypocalcemia type 1. N Engl J Med 389:1245\u20131247. https:\/\/doi.org\/10.1056\/NEJMc2302708","journal-title":"N Engl J Med"},{"key":"706_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","volume":"1","author":"M Mannstadt","year":"2013","unstructured":"Mannstadt M, Clarke BL, Vokes T et al (2013) Efficacy and safety of Recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275\u2013283. https:\/\/doi.org\/10.1016\/S2213-8587(13)70106-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"706_CR18","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1210\/jcem.83.10.5185","volume":"83","author":"KK Winer","year":"1998","unstructured":"Winer KK, Yanovski JA, Sarani B, Cutler GB Jr. (1998) A randomized, Cross-Over trial of Once-Daily versus Twice-Daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480\u20133486. https:\/\/doi.org\/10.1210\/jcem.83.10.5185","journal-title":"J Clin Endocrinol Metab"},{"key":"706_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMc2034981","volume":"385","author":"A Sastre","year":"2021","unstructured":"Sastre A, Valentino K, Hannan FM et al (2021) PTH infusion for seizures in autosomal dominant hypocalcemia type 1. N Engl J Med 385:189\u2013191. https:\/\/doi.org\/10.1056\/NEJMc2034981","journal-title":"N Engl J Med"},{"key":"706_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0140-6736(02)09842-2","volume":"360","author":"S Watanabe","year":"2002","unstructured":"Watanabe S, Fukumoto S, Chang H et al (2002) Association between activating mutations of calcium-sensing receptor and bartter\u2019s syndrome. Lancet 360:692\u2013694. https:\/\/doi.org\/10.1016\/S0140-6736(02)09842-2","journal-title":"Lancet"},{"key":"706_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/joneph\/19.4.525","volume":"19","author":"G Vezzoli","year":"2006","unstructured":"Vezzoli G, Arcidiacono T, Paloschi V et al (2006) Autosomal dominant hypocalcemia with mild type 5 Bartter syndrome. J Nephrol 19:525\u2013528","journal-title":"J Nephrol"},{"key":"706_CR22","doi-asserted-by":"publisher","unstructured":"Jones-Ryan ML, Desouza CV (2020) SAT-347 diagnosis of autosomal dominant hypocalcemia type 1 following the initiation of Imatinib for treatment of chronic myeloid leukemia. J Endocr Soc 4. https:\/\/doi.org\/10.1210\/jendso\/bvaa046.243","DOI":"10.1210\/jendso\/bvaa046.243"},{"key":"706_CR23","doi-asserted-by":"publisher","unstructured":"Marija Petri\u0107 Antonija miljak; Tanja mili\u010devi\u0107; Maja Radman A rare case of hypocalcemia induced by nilotinib. Endocr Oncol Metab 3:32\u201335. https:\/\/doi.org\/10.21040\/eom\/2017.3.1.5","DOI":"10.21040\/eom\/2017.3.1.5"},{"key":"706_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/0284186X.2020.1726455","volume":"59","author":"AMA van der Berends","year":"2020","unstructured":"van der Berends AMA, Oosting SF et al (2020) Hypocalcemia induced by tyrosine kinase inhibitors: targeted treatment with \u2018untargeted\u2019 side effects. Acta Oncol (Madr) 59:726\u2013729. https:\/\/doi.org\/10.1080\/0284186X.2020.1726455","journal-title":"Acta Oncol (Madr)"},{"key":"706_CR25","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.3390\/cancers13164116","volume":"13","author":"SA Mian","year":"2021","unstructured":"Mian SA, Bonnet D (2021) Nature or nurture?? Role of the bone marrow microenvironment in the genesis and maintenance of myelodysplastic syndromes. Cancers (Basel) 13:4116. https:\/\/doi.org\/10.3390\/cancers13164116","journal-title":"Cancers (Basel)"},{"key":"706_CR26","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41467-022-27973-x","volume":"13","author":"S-CA Yeh","year":"2022","unstructured":"Yeh S-CA, Hou J, Wu JW et al (2022) Quantification of bone marrow interstitial pH and calcium concentration by intravital ratiometric imaging. Nat Commun 13:393. https:\/\/doi.org\/10.1038\/s41467-022-27973-x","journal-title":"Nat Commun"},{"key":"706_CR27","doi-asserted-by":"publisher","first-page":"C461","DOI":"10.1152\/ajpcell.00389.2010","volume":"301","author":"JYC Chow","year":"2011","unstructured":"Chow JYC, Estrema C, Orneles T et al (2011) Calcium-sensing receptor modulates extracellular Ca 2 + entry via TRPC-encoded receptor-operated channels in human aortic smooth muscle cells. Am J Physiol Physiol 301:C461\u2013C468. https:\/\/doi.org\/10.1152\/ajpcell.00389.2010","journal-title":"Am J Physiol Physiol"},{"key":"706_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00432-007-0280-3","volume":"133","author":"D Breitkreutz","year":"2007","unstructured":"Breitkreutz D, Braiman-Wiksman L, Daum N et al (2007) Protein kinase C family: on the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol 133:793\u2013808. https:\/\/doi.org\/10.1007\/s00432-007-0280-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"706_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrc2168","volume":"7","author":"HJ Mackay","year":"2007","unstructured":"Mackay HJ, Twelves CJ (2007) Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 7:554\u2013562. https:\/\/doi.org\/10.1038\/nrc2168","journal-title":"Nat Rev Cancer"},{"key":"706_CR30","doi-asserted-by":"publisher","unstructured":"Mencalha A, Correa S, Abdelhay E (2014) Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development. Onco Targets Ther 1247. https:\/\/doi.org\/10.2147\/OTT.S64303","DOI":"10.2147\/OTT.S64303"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-025-00706-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00706-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:29:11Z","timestamp":1774380551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-025-00706-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s42000-025-00706-7","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required for a case report from our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}}]}}